Breaking News

You are here » Indian-Commodity  :  Commodities  :  Turmeric  :  Turmeric futures trade lower on profit-booking

09-Apr2018

Turmeric futures trade lower on profit-booking

Turmeric futures traded lower on NCDEX as market participants booked profits amidst sluggish demand in spot market. However, export demands for new season crop have capped some losses.

The contract for April delivery was trading at Rs 6394 .00, down by 0.93 % or Rs 60.00 from its previous closing of Rs 6454.00. The open interest of the contract stood at 4955 lots.

The contract for May delivery was trading at Rs 6462 .00, down by 0.95 % or Rs 62.00 from its previous closing of Rs 6524.00. The open interest of the contract stood at 10475 lots on NCDEX.


Related News

View all news

Turmeric futures trade higher on pick up in demand

Turmeric futures traded higher on NCDEX, in line with fresh buying at lower price levels amid anticipations on pick up in demand from domestic markets. However, reports on improved sowing in turmeric growing......

Turmeric futures trade higher on rise in demand

Turmeric futures traded higher on NCDEX, due to enlargement of position by speculators. Moreover, rise in demand from domestic spot markets also fuelled the uptrend.The contract for October delivery was......

Turmeric futures decline on higher arrivals

Turmeric futures traded lower on NCDEX, with the liquidation of bets tracking higher arrivals and improved sowing in turmeric growing areas of Tamilnadu, Karnataka and Maharashtra. Moreover, subdued demand......

Top News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......